Skip to content

KLOW Protocol

Tags: KLOW, Combination Peptide, GHK-Cu, TB-500, BPC-157, KPV

Quick Summary

KLOW is a four-peptide research combination (GHK-Cu, TB-500, BPC-157, KPV) designed for tissue repair, anti-inflammation, and cellular regeneration. No clinical trials exist for this specific combination; it remains investigational with theoretical benefits based on complementary mechanisms.

Quick Facts

  • Typical Dose: 200-500 mcg total blend (125–312 mcg GHK‑Cu, 25–62 mcg each other)
  • How Often: Once daily typical
  • Route: Injectable (subcutaneous; rotate abdomen, thighs, upper arms)
  • Cycle: 4–6 weeks reported (4–6 weeks on, 2–4 weeks off)
  • Storage: 2–8°C (refrigerated)

Overview

KLOW is a research peptide combination that builds upon the GLOW protocol by adding KPV for enhanced anti-inflammatory effects. This 80 mg blend typically contains 50 mg GHK‑Cu, 10 mg TB‑500, 10 mg BPC‑157, and 10 mg KPV in a 5:1:1:1 ratio. While individual components have varying levels of research support, no clinical trials have examined this specific four‑peptide combination. The protocol remains investigational with theoretical benefits based on complementary mechanisms.

Key Benefits

  • Theoretical synergistic effects from four peptides: tissue repair, anti‑inflammation, cellular regeneration
  • Potential enhanced tolerability and single‑injection convenience compared with administering separate peptides

Mechanism of action

Each peptide contributes different mechanisms: GHK‑Cu modulates gene expression, TB‑500 enhances cell migration, BPC‑157 upregulates growth factors, and KPV inhibits NF‑κB mediated inflammation.

Research indications

  • Wound Healing: Multi‑modal healing addressing tissue repair through complementary pathways.
  • Recovery: Effective in user reports for recovery and tolerability.
  • Anti‑Inflammatory: Moderate — KPV may reduce injection site reactions compared to GLOW.

Research protocols

Goal Dose Frequency Route
Common Research Protocol 200–500 mcg total (125–312 mcg GHK‑Cu, 25–62 mcg each other) Once daily Subcutaneous
Conservative Approach 200 mcg total daily Once daily evening Subcutaneous
Standard 80 mg Vial Protocol Reconstitute with 4 mL = 20 mg/mL, use 0.01–0.025 mL daily Once daily Subcutaneous
Cycling Protocol As above 4–6 weeks on, 2–4 weeks off Subcutaneous

Timing: Evening dosing is common practice but not research‑backed; some prefer morning administration.

Interactions

Compatible / Complementary

  • None documented for this specific combination

Monitor

  • GLOW Protocol — Use caution; overlapping peptides
  • Ipamorelin — Unknown interaction
  • NAD+ — Unknown interaction
  • Anticoagulants — Use caution
  • Immunosuppressants — Use caution

Avoid

  • Growth Hormone — Avoid combination

How to reconstitute

  1. Clean vial top with alcohol pad.
  2. Add 2–5 mL bacteriostatic water (4 mL creates 20 mg/mL).
  3. Gently swirl — do not shake.
  4. Solution should be clear to slightly cloudy.
  5. Label with date and concentration.
  6. Store in refrigerator immediately.
  7. Use within 4–6 weeks.

Quality Indicators

Positive Signs

  • Sourced from reputable research supplier with quality control processes
  • Batch information and ratios documented
  • Certificate of analysis (COA) provided

Warning Signs

  • Marketed for human therapeutic use (not research-only)
  • Batch variability with undocumented ratios or purity
  • No certificate of analysis provided
  • Unregulated market source with quality and contamination risks

What to expect

  • Individual responses vary widely with no predictable timeline.
  • Some users report reduced inflammation within days.
  • Wound healing effects may take 2–4 weeks if they occur.
  • No clinical data exists to set realistic expectations; placebo effects may contribute.

Side effects & safety

  • No safety studies on the four‑peptide combination.
  • Individual peptides generally well‑tolerated in research, but long‑term effects are unknown.
  • Injection site reactions are common even with KPV.
  • FDA has not approved any component for therapeutic use.
  • Quality and contamination risks exist in the unregulated market.

References

Individual Component Research - GHK-Cu (Multiple Studies)

  • Human studies | Various protocols | 40+ years research

GHK-Cu has extensive research showing wound healing, anti-aging, and gene modulation effects. However, these studies used GHK-Cu alone, not in combination.

BPC-157 Limited Human Data (2020)

  • Human pilot | 12 patients | Interstitial cystitis

One small pilot study showed 10 of 12 patients achieved complete resolution of interstitial cystitis symptoms. Most BPC-157 research remains in animal models.

No Published Studies on KLOW Combination

  • No clinical trials | No safety studies | No peer-reviewed research

Despite vendor claims and user reports, no scientific studies have examined the safety or efficacy of the four-peptide KLOW combination.

View Study → [N/A]